Zhejiang Shimai Pharmaceutical Co., Ltd.

浙江时迈药业股份有限公司

Clinical-stage biotech developing T-cell engager (TCE) therapies, including masked TCEs for solid tumors, targeting oncology markets in China and globally.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Supplier concentration
• Connected or related major customers / suppliers
• Outsourced production (OEM / contract manufacturing)
• Losses and path to profitability
• Cash burn and runway
• Non-recurring gains and losses
• Related-party transactions and balances
• Chapter 18A biotech